The price-to-earnings ratio for Elanco Animal Health Inc (NYSE: ELAN) is above average at 15.76x. The 36-month beta value for ELAN is also noteworthy at 1.45. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for ELAN is 489.91M, and at present, short sellers hold a 2.95% of that float. The average trading volume of ELAN on March 25, 2025 was 4.46M shares.
ELAN) stock’s latest price update
The stock of Elanco Animal Health Inc (NYSE: ELAN) has increased by 1.52 when compared to last closing price of 10.53. Despite this, the company has experienced a 0.47% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-03-23 that NEW YORK CITY, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ELAN.
ELAN’s Market Performance
ELAN’s stock has risen by 0.47% in the past week, with a monthly drop of -2.99% and a quarterly drop of -8.87%. The volatility ratio for the week is 3.21% while the volatility levels for the last 30 days are 3.82% for Elanco Animal Health Inc The simple moving average for the past 20 days is -0.52% for ELAN’s stock, with a -19.50% simple moving average for the past 200 days.
Analysts’ Opinion of ELAN
Many brokerage firms have already submitted their reports for ELAN stocks, with UBS repeating the rating for ELAN by listing it as a “Buy.” The predicted price for ELAN in the upcoming period, according to UBS is $18 based on the research report published on December 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see ELAN reach a price target of $14. The rating they have provided for ELAN stocks is “Market Perform” according to the report published on December 02nd, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to ELAN, setting the target price at $15 in the report published on September 19th of the previous year.
ELAN Trading at -5.68% from the 50-Day Moving Average
After a stumble in the market that brought ELAN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.14% of loss for the given period.
Volatility was left at 3.82%, however, over the last 30 days, the volatility rate increased by 3.21%, as shares sank -3.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.45% lower at present.
During the last 5 trading sessions, ELAN rose by +0.47%, which changed the moving average for the period of 200-days by -41.26% in comparison to the 20-day moving average, which settled at $10.75. In addition, Elanco Animal Health Inc saw -11.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELAN starting from Kurzius Lawrence Erik, who purchase 10,000 shares at the price of $10.90 back on Mar 07 ’25. After this action, Kurzius Lawrence Erik now owns 101,459 shares of Elanco Animal Health Inc, valued at $109,000 using the latest closing price.
Kurzius Lawrence Erik, the Director of Elanco Animal Health Inc, purchase 10,000 shares at $10.20 during a trade that took place back on Mar 11 ’25, which means that Kurzius Lawrence Erik is holding 111,459 shares at $102,000 based on the most recent closing price.
Stock Fundamentals for ELAN
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.46 for the gross margin
The net margin for Elanco Animal Health Inc stands at 0.08. The total capital return value is set at 0.02. Equity return is now at value 5.49, with 2.51 for asset returns.
Based on Elanco Animal Health Inc (ELAN), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 1.07.
Currently, EBITDA for the company is 1.39 billion with net debt to EBITDA at 7.75. When we switch over and look at the enterprise to sales, we see a ratio of 2.06. The receivables turnover for the company is 5.01for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.44.
Conclusion
In summary, Elanco Animal Health Inc (ELAN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
